Instituto Peruano para el Estudio y Abordaje Integral de la Personalidad, Personality Disorders, Calle Francia 329, Miraflores, Lima, 15074, Perú.
Sociedad Científica de Estudiantes de Medicina de la Universidad Nacional de Trujillo, Calle Salaverry # 545, Trujillo, La Libertad, 13011, Perú.
Psychiatr Q. 2023 Dec;94(4):541-557. doi: 10.1007/s11126-023-10045-8. Epub 2023 Aug 11.
Aripiprazole is an atypical antipsychotic medication, and its use in treating borderline personality disorder (BPD) is debatable because it is not FDA-approved for treating BPD. This study aimed to investigate the efficacy and safety of aripiprazole in patients with BPD. On July 2, 2021, the protocol (CRD42021256647) was registered in PROSPERO. PubMed, Scopus, Web of Science, Ovid-Medline, Embase, PsycINFO, and Cochrane (CENTRAL) were searched without regard for language or publication date. We also searched trial registries on ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform. Randomized clinical trials with adult patients diagnosed with BPD met the inclusion criteria. The Cochrane risk of bias for randomized trials (RoB-2) method was used to assess the quality of the included studies. We included two previously published randomized clinical trials. There were 76 patients with BPD, with 38, 12, and 26 assigned to the aripiprazole, olanzapine, and placebo groups, respectively. Most patients (88.16%) were females, with ages ranging from 22.1 to 28.14 yr. Aripiprazole has been proven to reduce anxiety, depression, anger, hostility, clinical severity, and obsessive-compulsive behavior, insecurity, melancholy, anxiety, aggressiveness/hostility, phobic anxiety, paranoid thinking, psychoticism, and somatization. The adverse effects were headache, insomnia, restlessness, tremor, and akathisia. The risk of bias was considerable in both trials, which is somewhat problematic considering that prejudice can lead to incorrect outcomes and conclusions. Aripiprazole has demonstrated encouraging outcomes in the treatment of patients with BPD. More randomized controlled studies are needed.
阿立哌唑是一种非典型抗精神病药物，其用于治疗边缘型人格障碍（BPD）的疗效存在争议，因为它未获得美国食品药品监督管理局（FDA）批准用于治疗 BPD。本研究旨在探讨阿立哌唑治疗 BPD 患者的疗效和安全性。2021 年 7 月 2 日，方案（CRD42021256647）在 PROSPERO 上注册。检索了 PubMed、Scopus、Web of Science、Ovid-Medline、Embase、PsycINFO 和 Cochrane（CENTRAL），但未考虑语言或出版日期。我们还在 ClinicalTrials.gov 和世界卫生组织国际临床试验注册平台上检索了试验注册处。符合纳入标准的是成人 BPD 患者的随机临床试验。采用 Cochrane 随机对照试验偏倚风险（RoB-2）方法评估纳入研究的质量。我们纳入了两项先前发表的随机临床试验。共有 76 名 BPD 患者，其中 38 名、12 名和 26 名患者分别被分配到阿立哌唑、奥氮平组和安慰剂组。大多数患者（88.16%）为女性，年龄在 22.1 至 28.14 岁之间。阿立哌唑已被证明可降低焦虑、抑郁、愤怒、敌意、临床严重程度和强迫行为、不安全感、忧郁、焦虑、攻击性/敌意、恐怖性焦虑、偏执思维、精神病和躯体化。不良反应为头痛、失眠、不安、震颤和静坐不能。两项试验的偏倚风险均相当大，这在某种程度上是有问题的，因为偏见可能导致错误的结果和结论。阿立哌唑在治疗 BPD 患者方面显示出令人鼓舞的结果。需要更多的随机对照研究。
